Administration of Anti-SARS-CoV-2 Monoclonal Antibodies After US Food and Drug Administration Deauthorization.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 36036937.
- Also identified by DOI 10.1001/jamanetworkopen.2022.28997 and PMC identifier 9425149.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
This cross-sectional study uses time-series data to evaluate the administration of bamlanivimab-etesevimab and casirivimab-imdevimab monoclonal antibody treatments for SARS-CoV-2 infection after the US Food and Drug Administration deauthorized their use in early 2022.
Medical subject headings
- COVID-19